rev:       December 8, 2004

HOME (index page)

Return ( alphabetical antibody index page)

Return  (neurohistology ab index page)


ANTIBODIES  

(anti-Human and others as indicated)

RDI Division of Fitzgerald Industries Intl  offers a wide line of  antibodies. Since no one antibody works best for all applications (neutralization, blotting, histochemistry, ELISA, etc), we offer many different types of antibodies to help solve this problem. Please inquire for other applications or types of antibodies not listed below.


RAGE (see below 3 polyclonals for RAGE)
Product:               Receptor for Advanced Glycosylation End products (RAGE)  N Term Antiserum

Cat No:                RDI-RAGEabG       $312.00/0.25ml

Host:                   Goat

Immunogen:          Synthetic peptide: 42 PKKPPQRLEWKLNTGRTE 59

Form:                  Whole serum

Concentration:      N/A

Supplied as:          0.25ml vials

 Titer:                 Suggested working dilution using neat serum:

                                    ELISA using immunizing peptide: approx 1: 260,676

                       IHC using formalin-fixed, paraffin-embedded sections: approx1:400

                                  IHC using paraformaldehyde-fixed, frozen sections: N/D

                                 Western blots: N/D


Specificity:           Amino acid sequence 42-59 of human receptor

                         for advanced glycated end  products.

Preservative:        0.1% Sodium Azide   

                        (available azide free cat#RDI-RAGEabGX $1188.00/1ml)

Storage:               Short term: Refrigerate at 4º C     Long term:    Freeze at -20º C

 FOR RESEARCH AND MANUFACTURING USE ONLY

 * Various assay conditions require that the optimum working concentrations be determined by serial dilutions of this product.


Product: Human Receptor for Advanced Glycosylation End Products (RAGE) N-terminal Peptide Antiserum

RAGE is a member of the immunoglobulin superfamily of cell surface molecules that binds molecules that have been irreversibly modified by non-enzymatic glycation and oxidation, and are know as advanced glycation end products (AGEs).  It is expressed by endothelium, mononuclear phagocytes, neurons and smooth muscle cells.  Whereas RAGE is present at high levels during development, especially in the central nervous system, its levels decline during maturity.

The increased expression of RAGE is associated with several pathological states, such as diabetic vasculopathy, neuropathy, retinopathy and neuropathy, and other disorders, including Alzheimer’s disease and immune/inflammatory reactions of the vessel walls.  In diabetic tissues, the production of RAGE is due to the overproduction of AGEs that eventually overwhelm the protective properties of RAGE.  This results in oxidative stress and endothelial cell dysfunction that leads to vascular disease in diabetics.  In the brain, RAGE also binds amyloid beta (AE).  Because AE is overproduced in neurons and vessels in the brains of Alzheimer disease, this leads to the hyperstimulation of RAGE.  The RAGE-AE interaction is thought to result in oxidative stress leading to neuronal degeneration.

 A goat antiserum to a synthetic peptide that corresponds to amino acids 42-59 of the N-terminus of human RAGE protein is currently available. This antiserum has been shown to be immunoreactive with the unconjugated immunizing peptide by ELISA.  It will also immunolabel vessels from diabetic tissues and vessels and neurons from the brains of AD patients in formalin-fixed, paraffin-embedded tissues. This antibody should be a valuable tool for scientists working to understand the role of RAGE in diabetes and AD.

 This antiserum was produced using proprietary methodology whereby the peptide is attached to a carrier that elicits minimal immunoreactivity so that the antiserum has a higher degree of specificity for the peptide.  Since there is no overwhelming production of interfering antibodies to the carrier, this antiserum can routinely be used without further purification.  A control immune serum (Cat no.RDI-GPA018E  $315.00/500 µl ) from a mock immunized animal is available to be used in conjunction with this antibody as well as the immunizing peptide (Cat no. RDI-RAGE-AG, $312.00/1mg), which can be used to neutralize immunoreactivity.

 

 

Human diabetic kidney showing immunohistochemical staining of blood vessels in formalin-fixed, paraffin-embedded section at 1:400 dilution.


Product: Receptor for Advanced Glycosylation End products (RAGE) C-terminal Antiserum

Cat No: RDI-RAGECabG   $315.00/250µl

Lot No:

Host: Goat

Immunogen: Synthetic peptide: 385 RAELNQSEEPEAGES 399

Form: Whole serum

Concentration: N/A

Titer: Suggested working dilution using neat serum:*

          -ELISA using immunizing peptide: 1:5,000

          - IHC using formalin-fixed, paraffin-embedded sections: 1:400

          - IHC using paraformaldehyde-fixed, frozen sections: N/D

           - Western blots: N/D

Specificity: Amino acid sequence 385-399 of human receptor for advanced glycated end products.

Preservative: 0.1% Sodium Azide

Bulk available without azide cat#RDI-RAGECabGXP $1125.0/1ml

Storage: Short term: Refrigerate at 4º C

Long term: Freeze at -20º C

.

also available: Pseud-Immune™ control immune serum (RDI- GPA018E $312.00/0.5ml) from a mock immunized animal is available to be used in conjunction with this antibody as well as the immunizing peptide (Cat no. RDI-RAGEC-CP $312.00/1mg), which can be used to neutralize immunoreactivity.

FOR RESEARCH AND MANUFACTURING USE ONLY

· Various assay conditions require that the optimum working concentrations be determined by serial dilutions of this product.

The Receptor for Advanced Glycosylated End Products (RAGE) is a member of the immunoglobulin superfamily of cell surface proteins that binds molecules that have been irreversibly modified by non-enzymatic glycation and oxidation. They are known as advanced glycation end products (AGEs). It is expressed by endothelium, mononuclear phagocytes, neurons and smooth muscle cells. Whereas RAGE is present at high levels during development, especially in the central nervous system, its levels decline during maturity.

The increased expression of RAGE is associated with several pathological states, such as diabetic vasculopathy, retinopathy and neuropathy, and other disorders, including Alzheimer's disease and immune/inflammatory reactions of the vessel walls. In diabetic tissues, the production of RAGE is due to the overproduction of AGEs that eventually overwhelm the protective properties of RAGE. This results in oxidative stress and endothelial cell dysfunction that leads to vascular disease in diabetics. In the brain, RAGE also binds amyloid beta (Ab). Because Ab is overproduced in neurons and vessels in the brains of Alzheimer disease, this leads to the hyperstimulation of RAGE. The RAGE-Ab interaction is thought to result in oxidative stress leading to neuronal degeneration.

A goat antiserum to a synthetic peptide that corresponds to amino acids 385-399 of the C-terminus of human RAGE protein is currently available. This antiserum has been shown to be immunoreactive with the unconjugated immunizing peptide by ELISA. It will also immunolabel AGE from diabetic tissues in formalin-fixed, paraffin-embedded tissues. This antibody should be a valuable tool for scientists working to understand the role of RAGE in diabetes and AD.

This antiserum was produced using proprietary methodology whereby the peptide is attached to a carrier that elicits minimal immunoreactivity so that the antiserum has a higher degree of specificity for the peptide. Since there is no overwhelming production of interfering antibodies to the carrier, this antiserum can routinely be used without further purification. Pseud-Immune™ control immune serum (RDI- GPA018E $312.00/0.5ml) from a mock immunized animal is available to be used in conjunction with this antibody as well as the immunizing peptide (Cat no. RDI-RAGECabG-CP $315.00/1mg), which can be used to neutralize immunoreactivity.

For In Vitro Research Use Only


Rabbit anti-RAGE (Rat/Mouse)

cat# RDI-RAGECabrX      $469.00/100ul

Package: 100 ug in 0.1ml (1mg/ml) of affinity purified rabbit   serum with 1.0 mg/ml BSA and 0.05% sodium azide. Store at -20C. Avoid repeated freeze/thaw cycles.

Immunogen: Synthetic peptide:   C(362) W R K R Q P R (R/L) E E R K A P E S Q E D(NH2)(380)

The immunizing peptide corresponds to amino acid residues 362-380 from rat RAGE. This sequence is 100% conserved in mouse and 70% conserved in humans.

The immunizing peptide (Cat#RDI-RAGECRX-CP $156.00) is available for use in neutralization and control experiments.

Use: -Immunohistochemistry (Frozen) 1 ug/ml

        -Western Blot 1-2 ug/ml

This antibody has been successfully used in Western   blot and immunohistochemistry procedures. By Western blot, this antibody detects two bands in the 45 kDa range representing the RAGE protein pre and post-glycosylation in mouse lung extract. This antibody also detects an ~25 kDa protein that is believed to be proteolytic degradation product. Immuno-histochemical staining of RAGE in transgenic mouse retina results in staining of the retinal pigmented epithelium and photo receptor cell layers.

Storage: Store at -20 DEG C upon receipt. Avoid frequent freeze thaw cycles. Recommend aliquoting. BEFORE OPENING, suggest centrifuging for 1 minute at 1000 RPM to concentrate material in vial. Do not aliquot in same volumes less than 20ul without diluting into buffer containing 1-5% BSA or other carrier (to prevent absorption onto vial surface.

Background: The receptor for advanced glycation endproducts (RAGE)   is a member of the Immunoglobin superfamily of cell surface markers. This protein is able to interact with many molecules including: advanced glycation endproducts (AGE), amphoterin, and ligands.   Research has shown that the accumulation of RAGE ligands in the biological system (endothelium mononuclear phagocytes, neurons and smooth muscle cells) can lead to destructive tissue diseases such as diabetic retinopathy, amyloidoses, tumors and inflammation disorders.

See also Goat anti-Human Rage Antibodies

For Research Use Only


RDI Division of Fitzgerald Industries Intl

34 Junction Square Drive

Concord MA 01742-3049

USA

phone (978) 371-6446 or (800) 370-2222

fax     (978) 371-2266

EMAIL:antibodies@fitzgerald-fii.com

Ordering terms

RETURN(neurohistology ab page)

Return ( alphabetical antibody index page)